SR 146131 - 10mM in DMSO , CAS No.221671-61-0

CAS: 221671-61-0 Cat. No.: S655213 Formula: C₃₂H₃₆ClN₃O₅S Molecular Weight: 610.16 PubChem CID: 9852833

GRADE & PURITY 10mM in DMSO

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Overview

SR 146131 is a potent, orally available, and selective nonpeptide ( cholecystokinin 1 ) receptor agonist.

In Vitro

SR 146131 inhibits in the binding of [ 125 I]-BH-CCK-8S to CCK1sites on 3T3-hCCK1 cell membranes with an IC 50 value of 0.56 ± 0.10 nM. At much higher concentrations, SR 146131 also inhibits the binding of radiolabeled CCK to CCK2sites in CHO-hCCK2 membranes with an IC 50 of 162 ± 27 nM. SR 146131 is a potent CCK1 agonist on several intracellular events linked to CCK1 receptor activation in various cell types: on [Ca 2+ ]i release and IP1 formation, SR 146131 appears as a full CCK1 receptor agonist in the 3T3-hCCK1 cells, but a partial CCK1receptor agonist on MAPK activation and early gene expression in this cell line. SR 146131 also acts as a partial agonist in the two neuroblastoma cell lines. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

SR 146131 completely inhibits gastric and gallbladder emptying in mice (ED 50 of 66 and 2.7 μg/kg p.o., respectively). SR 146131 dose dependently reduces food intake in fasted rats (from 0.1 mg/kg p.o.), in nonfasted rats in which food intake has been highly stimulated by the administration of neuropeptide Y (1–36) (from 0.3 mg/kg p.o.), in fasted gerbils (from 0.1 mg/kg p.o.), and in marmosets maintained on a restricted diet (from 3 mg/kg p.o.). SR 146131 (10 mg/kg p.o.) also increases the number of Fos-positive cells in the hypothalamic paraventricular nucleus of rats. Locomotor activity of mice is reduced by orally administered SR 146131 (from 0.3 mg/kg p.o.) . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

IC50& Target:Cholecystokinin 1 receptor

Specifications

Specifications & Purity

10mM in DMSO

Biochemical and Physiological Mechanisms

SR 146131 is a potent, orally available, and selective nonpeptide ( cholecystokinin 1 ) receptor agonist.

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

This product requires cold chain shipping. Ground and other economy services are not available.

Names and Identifiers

Isomeric SMILES

CC1=CC(=C2C(=C1)C=C(N2CC(=O)O)C(=O)NC3=NC(=C(S3)CCC4CCCCC4)C5=CC(=C(C=C5OC)Cl)OC)C

Alternate CAS

221671-61-0

PubChem CID

9852833

MeSH Entry Terms

2-(4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)thiazol-2-ylcarbamoyl)-5,7-dimethylindol-1-yl-1-acetic acid;SR 146131;SR-146131;SR146131

Molecular Weight

610.16

Associated Targets(Human)

CCKAR Tclin Cholecystokinin receptor type A (0 Activities)

Discover Target: CCKAR

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Application Protocols

No tested application protocols are provided for this item.

General practices for small-molecule assay deployment

• Stock preparation: Dissolve in anhydrous DMSO to prepare a concentrated stock (e.g., 10–50 mM). Filter if particulate remains (0.22 µm PTFE) and aliquot to minimize freeze–thaw.
• Plate-based assays: Normalize final DMSO across wells (typ. 0.1–1.0% v/v). Prepare serial dilutions in DMSO or buffer with co-solvent, mix thoroughly, and pre-wet tips to improve accuracy.
• Stability checks: Run time-course UV/LC–MS on working solutions stored at room temperature, 4°C, and assay temperature to rule out degradation.
• Data integrity: Include vehicle and background controls; consider counter-screens for fluorescence/absorbance interference.

Note: These are general guidelines, not item-specific instructions. Validate and adapt to your assay and institutional SOPs.

Biological Roles

Item-specific biological target(s), mechanism of action, and pathway roles for SR 146131 are not provided in the Product Data. Do not infer pharmacology without primary references.

General guidance for small-molecule research tools

• Define the biological hypothesis a priori and confirm the compound’s identity/purity before drawing mechanistic conclusions.
• If literature suggests a receptor/enzyme interaction for SR 146131, validate in your system with concentration–response curves, ligand displacement or activity assays, and appropriate orthogonal methods (e.g., target engagement via CETSA or NanoBRET where applicable).
• Assess off-target risks using selectivity panels or predictive in silico profiling (when the structure is available). Counter-evaluate cytotoxicity (e.g., CellTiter-Glo) and nonspecific membrane effects to contextualize activity readouts.
• Consider species differences in potency/efficacy if using nonhuman models; lot-to-lot consistency and salt form can shift apparent potency.

Note: This product is supplied strictly for research use only. No medical, diagnostic, or therapeutic applications are intended or implied.

Buffer Applications

This item is a small-molecule research compound, not a buffering agent. It does not define or maintain pH and is not typically used to prepare buffer systems.

Practical notes

• When dosing into buffered assays, maintain constant final solvent (e.g., DMSO 0.1–1.0% v/v) across all wells/tubes to avoid pH or activity artifacts.
• Verify compatibility of the compound with your buffer salts (e.g., PBS, HEPES, Tris) and additives (detergents, BSA) by observing for precipitation or adsorption losses.
• If pH-dependent stability is suspected, perform a small pH-stability scan (e.g., pH 5–9) before large studies.

Green Alternatives

For handling SR 146131 solutions, the primary environmental impacts arise from solvent selection and waste management rather than the compound itself.

Greener solvent considerations (general)

• Prefer ethanol or water-based cosolvent systems where compatible with solubility and assay design; they offer lower toxicity and improved biodegradability versus polar aprotic solvents.
• If high solvency is required, consider Cyrene or propylene carbonate as greener alternatives to DMF/DMSO in non-biological workflows; confirm compound stability and assay tolerance first.

Comparison (general guidance)

• DMSO: Excellent solvency and biocompatibility; moderate environmental profile; ubiquitous in screening.
• Ethanol: Renewable routes available; volatile and easy to remove; limited solvency for very lipophilic compounds.
• PEG-400 + water: Enhances solubility for hydrophobic molecules; high viscosity can affect liquid handling.
• HP-β-cyclodextrin (aq.): Enables aqueous delivery of hydrophobes; biodegradable; may interact with membranes/proteins—assess assay impact.

Operational tips

• Minimize total solvent volumes; employ micro-aliquoting and sealed vials to extend stock life.
• Consolidate organic waste streams and label by solvent class to facilitate compliant disposal.

Note: Select the greenest option that maintains data quality; verify target readouts are unaffected by the chosen solvent system.

Pharmaceutical Uses

No pharmacopeial status, excipient role, or manufacturing/formulation use is provided for this item.

Context and guidance

• As supplied, SR 146131 is designated for research use only. It is not intended for human or veterinary use, clinical diagnosis, or as a drug substance/excipient.
• If used as an internal reference standard or control article in preclinical research, document lot-specific identity/purity, salt form, and storage conditions. Where regulatory filings are anticipated, ensure sourcing and analytical controls meet applicable internal QA standards.
• Avoid extrapolating in vitro findings to clinical contexts; confirm ADME and safety profiles through appropriate, ethics-approved studies if required by your organization’s research roadmap.

Physical Properties

Item-specific specifications are not provided in the Product Data. Do not assume values; consult the CoA/SDS.

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Melting point (MP): Not specified for this item; refer to CoA/Spec Sheet.
• Boiling point (BP): Not specified for this item; refer to CoA/Spec Sheet.
• Density: Not specified for this item; refer to CoA/Spec Sheet.
• Solubility: Not specified for this item; refer to CoA/Spec Sheet. Practical guidance is in “Solvent Selection.”
• LogP/logD: Not specified for this item; refer to CoA/Spec Sheet.
• pKa: Not specified for this item; refer to CoA/Spec Sheet.
• Refractive index/UV cutoff: Not specified for this item; refer to CoA/Spec Sheet.

Practical notes (general guidance)

• For small-molecule library members with unknown solubility, begin with DMSO screening (1–30 mg/mL), then evaluate miscibility with water or assay buffer via serial dilution with surfactant (0.01–0.1% Tween-20) when compatible.
• If crystalline, gentle warming (25–40°C) and vortex/sonication can aid dissolution; avoid prolonged heating unless thermal stability is documented on the CoA.
• Record the exact solvent, concentration, and lot number in assay notebooks to ensure reproducibility across screenings.

Quality and Grades

• Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.

How to interpret grade (general guidance)

• Research-grade small molecules typically emphasize identity (1H NMR/LC–MS) and purity by HPLC/UPLC. When UV-Vis chromatograms are provided, verify both area % and the detection wavelength. For bioassays, impurities at even 1–2% can confound SAR—request full analytical package when critical.
• If offered as “screening grade,” expect high purity (commonly ≥95% by HPLC, literature) with minimal characterization focused on fit-for-purpose screening; if “analytical” or “reference standard” grade is needed, confirm assay, residual solvents, and water content by Karl Fischer.

Stabilizers and counterions

• Stabilizer: Not specified for this item; refer to CoA/Spec Sheet. If present, note its potential interference with bioassays.
• Salt form / counterion: Not specified for this item; refer to CoA/Spec Sheet. The salt state strongly affects solubility and pH of stock solutions.

Recommendations

• Request: detailed CoA (HPLC trace, MS, NMR), salt form, residual solvent profile, water content, and any chirality data. Align analytical controls with your intended application (e.g., GLP screening vs. discovery assays).

Reaction and Applications

This product is positioned as a small-molecule library member rather than a synthetic reagent. No manufacturer application notes are provided for chemical reactions.

Research applications (general)

• Reference compound in high-throughput screening (HTS), hit validation, and mechanistic assays where SR 146131 is known/assumed to interact with a biological target in your assay system. Confirm exact target and potency from primary literature before use.
• Tool compound usage in cellular or biochemical assays to probe pathway dependence, receptor occupancy, or as a positive/negative control once target identity is confirmed.

Practical guidance

• Prepare concentrated DMSO stocks (see Solvent Selection) and dispense using low-retention tips. For plate-based assays, equalize final DMSO across wells to avoid solvent bias.
• If used for SAR benchmarking, run orthogonal readouts (e.g., biochemical vs. cell-based) to control for assay interference (fluorescence quenching, redox activity, aggregation).
• Implement counter-screens (e.g., detergent-sensitive aggregation tests, redox-cycling detection with HRP/resazurin) to rule out pan-assay interference compounds (PAINS) behavior.

Note: No specific reaction chemistry (e.g., cross-coupling, condensation) is applicable here given the lack of structural and functional group disclosure.

Reaction Conditions

Not applicable. This product is not positioned as a chemical reagent for synthesis, and no item-specific reaction conditions are provided.

If employing derivatization for analytical purposes (general)

• Conjugation or tagging steps (e.g., forming reporter-labeled analogs) should be designed only after the exact structure is confirmed. Optimize solvent, temperature, and base/acid conditions around the known functional groups.
• Maintain an analytical baseline (LC–MS, HPLC purity) before and after any modification to confirm integrity and absence of degradation byproducts.

Safety and Handling

Hazard classification for this specific item is not provided in the Product Data. Always consult the product SDS for authoritative information.

• GHS classification: Not specified for this item; refer to SDS.
• Signal word / H-statements / Pictograms: Not specified for this item; refer to SDS.

General laboratory precautions (small-molecule screening compounds)

• PPE: Lab coat, safety glasses, and appropriate chemical-resistant gloves (e.g., nitrile). Avoid inhalation of dusts/aerosols. Handle powders in a fume hood or ventilated enclosure.
• Storage incompatibilities: Until specific data are known, segregate from strong oxidizers, strong acids/bases, and reducing agents. Protect from light and moisture unless stability data indicate otherwise.
• Hygiene: Wash hands after handling; do not eat, drink, or smoke in work areas. Prevent environmental release; dispose of waste per institutional and local regulations.
• First aid (overview; see SDS): Eye/skin contact—rinse with water for ≥15 minutes; remove contaminated clothing. Inhalation—move to fresh air. Ingestion—rinse mouth; seek medical attention. Provide SDS to responders.
• Weighing and solution prep: For microgram–milligram quantities, use anti-static precautions and weigh boats/lined spatulas to minimize loss and exposure.

Note: Many heteroaromatic or halogenated research compounds can be harmful if swallowed or inhaled; adopt a conservative risk posture in the absence of detailed hazard data.

Solvent Selection

Without a disclosed structure for SR 146131, choose solvents using a tiered, assay-compatible approach.

Primary stock solvent

• DMSO: Default for discovery libraries due to broad solvency and assay compatibility. Start at 10–50 mM stocks. Filter-sterilize when required (0.22 µm PTFE). Verify assay tolerance (typically ≤0.5–1.0% v/v).

Secondary organic cosolvents (if DMSO is insufficient)

• N,N-Dimethylformamide (DMF) or N-methyl-2-pyrrolidone (NMP): High solvency; confirm assay tolerance and mitigate leachables from plastics (prefer glass vials).
• Ethanol or methanol: Useful for less polar compounds with better aqueous dilution behavior than pure DMSO in some systems.

Aqueous handling

• Prepare aqueous working solutions by stepwise dilution of DMSO stocks into buffer under vortexing. Include surfactant (e.g., 0.01–0.05% Tween-20) if compatible to reduce precipitation.
• For poorly soluble compounds, consider co-solvent systems (e.g., 2–10% DMSO + 10–20% PEG-400 in buffer) or cyclodextrin inclusion (e.g., 5–20% w/v HP-β-CD), pending assay constraints.

Material compatibility and stability

• Prefer borosilicate glass for concentrated stocks; minimize freeze–thaw.
• Evaluate photostability (wrap in foil) and hydrolytic stability (pH 2–9 screening) empirically if no data are provided.

Documentation

• Record solvent, concentration, pH, and any visible precipitation after dilution. Retain aliquots for stability tracking.

Storage and Reconstitution

Storage and shipping (item-specific)

• Storage conditions: Store at -80°C (per Product Data). Keep tightly sealed, desiccated, and protected from light unless otherwise indicated on the CoA.
• Shipped in: Dry ice packs + Cold packs (per Product Data). Inspect upon receipt; if thawing occurred, consult QA before use.

Reconstitution (general guidance; not item-specific)

• Solvent: Use anhydrous DMSO as first-line solvent unless the CoA indicates a specific salt form favoring aqueous media. Start at 10–50 mM.
• Technique: Equilibrate vial to room temperature in a desiccator before opening to prevent condensation. Weigh quickly, cap promptly, and purge headspace with inert gas if available.
• Aliquoting: Prepare single-use aliquots in amber glass vials or low-bind tubes. Minimize headspace; store at -80°C.
• Freeze–thaw: Avoid repeated cycles. If thawed, keep on ice during use and promptly refreeze remaining aliquots.
• Stability: Lot-specific stability and any hygroscopic/photolabile behavior are Not specified for this item; refer to CoA/Spec Sheet. Perform small-scale stability checks in your intended solvent and temperature.

Disposal

• Collect unused solutions and waste in appropriate organic waste containers. Follow institutional and local regulations.

Research Use Note: For research use only.

Structure and Identity

• Product name: SR 146131 (SKU: S655213)
• CAS: 221671-61-0
• PubChem CID: 9852833
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.

Structural features

• Item-specific structural descriptors (ring systems, functional groups, stereochemistry): Not specified for this item; refer to CoA/Spec Sheet.

Notes

• SR 146131 is listed in small-molecule/compound library collections. Without a provided structure, do not infer functional groups or physicochemical behavior. For unambiguous identification (QC, regulatory records), request the exact structure (SMILES, InChI) and corroborate with the CAS and CID on the accompanying Certificate of Analysis (CoA).

Synthetic Utility

SR 146131 is sold as a small-molecule research tool rather than a building block or reagent. Without a disclosed structure, no meaningful synthetic transformations or retrosynthetic roles can be described for this specific item.

General notes (when structure becomes available)

• Identify functional handles (e.g., aryl halides, amines, carboxylates) to plan analog synthesis, prodrugs, or bioconjugates.
• If chiral, establish stereochemical integrity (chiral HPLC) and consider asymmetric synthesis routes or resolution methods for analog campaigns.
• For impurity profiling or metabolite synthesis, map plausible oxidation/reduction/conjugation hot spots and design selective transformations accordingly.

At present, treat SR 146131 primarily as a reference or probe compound rather than a synthetic intermediate.

Target Specificity

• Target/Pathway: Not specified for this item; refer to primary literature and CoA/Spec Sheet.
• Species selectivity or off-target profile: Not specified for this item; refer to literature.

Guidance

• Before using SR 146131 as a tool compound, confirm its reported target(s), potency (IC50/EC50/Ki), and selectivity in the context of your assay. Include appropriate positive/negative controls and, where possible, a structurally unrelated comparator acting on the same target.